<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://www.pharmanow.live/latest-news/hikma-umang-vohra-board</loc>
    <lastmod>2026-11-17T15:24:34+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Hikma Pharmaceuticals Appoints Ex-Cipla CEO Umang Vohra to Board</news:title>
      <news:keywords>Hikma Pharmaceuticals, Umang Vohra, Cipla, Non-Executive Director, Board of Directors, Cohance Lifesciences, generic pharmaceuticals</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/hikma-umang-vohra-board-appointment20261117152302.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/ideaya-biosciences-fda-type-c-ide849-registrational-strategy-neuroendocrine-carcinomas</loc>
    <lastmod>2026-11-18T12:08:42+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>IDEAYA Biosciences Aligns with FDA on IDE849 Trial Strategy</news:title>
      <news:keywords>IDEAYA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/ideaya-ide849-fda-type-c-nec-registrational-trial-strategy20261118120309.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/genentech-fda-approval-giredestrant-everolimus-esr1-mutated-metastatic-breast-cancer</loc>
    <lastmod>2026-11-18T11:55:21+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>FDA Approves Giredestrant Plus Everolimus for Breast Cancer</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-giredestrant-wilserdly-everolimus-esr1-breast-cancer-approval20261118115412.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/cue-biopharma-phase-2-csu-durability-data-cue-401-first-in-human-dosing</loc>
    <lastmod>2026-11-18T11:45:59+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Cue Biopharma Reports Phase 2 CSU Data and CUE-401 Dosing</news:title>
      <news:keywords>Cue Biopharma</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/cue-biopharma-cue-221-csu-durability-cue-401-phase-1-dosing20261118114346.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/mankind-pharma-signs-exclusive-india-deal-betta-pharmaceuticals-ensartinib-alk-nsclc</loc>
    <lastmod>2026-11-18T11:40:20+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Mankind Pharma Secures Exclusive India Rights for Ensartinib</news:title>
      <news:keywords>Mankind</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/mankind-pharma-ensartinib-betta-india-licensing-deal-alk-lung-cancer20261118113652.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/lantheus-achieves-phase-3-endpoints-tauklarify-tau-pet-early-alzheimers</loc>
    <lastmod>2026-11-18T11:26:14+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Lantheus Meets Phase 3 Endpoints for TAUKLARIFY PET</news:title>
      <news:keywords>Lantheus</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/lantheus-tauklarify-phase-3-early-alzheimers-tau-pet-results20261118112442.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/ucb-fda-approval-klygefa-dual-binding-nanobody-c5-inhibitor-gmg</loc>
    <lastmod>2026-11-17T11:29:01+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>UCB Gains FDA Approval for Klygefa as First Dual-Binding Nanobody C5 Inhibitor</news:title>
      <news:keywords>UCB</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/bf9c78ec-f5fb-44f9-8827-7c34bfabed8b/2981ecf6-4533-40b9-bcba-3c3ded747cc1.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/novartis-cosentyx-chmp-positive-opinion-adolescent-hidradenitis-suppurativa-europe</loc>
    <lastmod>2026-11-18T11:20:02+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T00:00:00+05:30</news:publication_date>
      <news:title>Novartis Gains Positive CHMP Opinion for Cosentyx in Adolescents</news:title>
      <news:keywords>Novartis</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/novartis-cosentyx-chmp-opinion-adolescent-hidradenitis-suppurativa20261118111904.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/evotec-secures-2-9-million-gates-foundation-grant-stem-cell-fetal-safety-screening</loc>
    <lastmod>2026-11-18T11:05:09+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T00:00:00+05:30</news:publication_date>
      <news:title>Evotec Secures $2.9M Grant for Stem Cell Fetal Safety</news:title>
      <news:keywords>Evotec</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/evotec-gates-foundation-grant-stem-cell-fetal-safety-screening20261118110329.webp</image:loc>
    </image:image>
  </url>
</urlset>